Executives

Yong Soon Ahn EVP(Executive Vice President)

Contents

Yong Soon Ahn was an EVP(Executive Vice President) and advisor of Vastera, adeveloper of drugs such as PAH(Pulmonary Arterial Hypertension), Alzheimer, TNBC(Triple-Negative Breast Cancer) and dryAMD. He has led the company\'s Global Licensing and partnering since 2018. In addition, as a global licensing expert who successfully completed the global licensing of Korea University College of Medicine\'s antibody technology in 2022, he has performed Global Licensing of numerous bio/new drug technologies, including bio/new drug technologies developed at several Universities and several Biotech\'s drug candidates of small molecules, Antibodies and novel platform technologies for nearly 20 years since 2007.

Based on this abundant experience in Global Licensing, he will assist customers for Global Business Developments, Global Licensing and Partnering for Bio/New Drug technologies and discover promising technologies to the successful final technology transfer.

MBA

Completed Doctoral Courses of Pharmacy at College of Pharmacy of Yonsei Univ.,

Technology Commercialize Valuation Agent

Technology Transaction Agency

Career

Yong Soon Ahn was an EVP(Executive Vice President) and advisor of Vastera, adeveloper of drugs such as PAH(Pulmonary Arterial Hypertension), Alzheimer, TNBC(Triple-Negative Breast Cancer) and dryAMD. He has led the company\'s Global Licensing and partnering since 2018. In addition, as a global licensing expert who successfully completed the global licensing of Korea University College of Medicine\'s antibody technology in 2022, he has performed Global Licensing of numerous bio/new drug technologies, including bio/new drug technologies developed at several Universities and several Biotech\'s drug candidates of small molecules, Antibodies and novel platform technologies for nearly 20 years since 2007.
Based on this abundant experience in Global Licensing, he will assist customers for Global Business Developments, Global Licensing and Partnering for Bio/New Drug technologies and discover promising technologies to the successful final technology transfer.
MBA
Completed Doctoral Courses of Pharmacy at College of Pharmacy of Yonsei Univ.,
Technology Commercialize Valuation Agent
Technology Transaction Agency